3 Dividend Aristocrats that you must have in portfolio

AbbVie (ABBV)

AbbVie (NYSE:ABBV), a pharmaceutical behemoth, might be one of your portfolio’s three dividend aristocrats. The company’s many treatments, including as Humira for a variety of autoimmune illnesses, give it fundamentally remarkable importance. AbbVie, however, expects to gain greatly from certain societal dynamics as a result of its acquisition of Allergan.

With the introduction and widespread use of video-sharing platforms like YouTube and TikTok, today’s youngsters are preoccupied with looking and feeling as youthful and as healthy as possible. I predict that members of Generation Y, Z, and the next one will have a particularly hard time maturing out of their youth. Therefore, I believe that long-term demand for ABBV stock will dramatically increase.

AbbVie’s forward yield of 3.97% is much higher than the industry average of 1.58% while you wait. Furthermore, it has a record of 51 years of dividend growth. Its payout ratio of 53.2%, although high relative to others, is nevertheless manageable. With a price objective of $170, analysts see 14% upside potential for ABBV.

PepsiCo (PEP)

PepsiCo (NASDAQ:PEP), a strong leadoff bat, attracts patient investors since its current difficulties are expected to be short-lived. PEP’s…